Sugi Predict

Sugi Predict / Compounds / SCHEMBL30924734

SCHEMBL30924734

SCHEMBL30924734

CC(C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CS)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)CN)C(=O)N[C@@H](CS)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)NCC(=O)O

nearest known ligand 0.57

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
▸ IL23R Q5VWK5 16/20 0.57
▸ TFPI P10646 1/20 0.56
▸ NPY4R P50391 2/20 0.51
▸ NPY1R P25929 1/20 0.51
▸ NPY2R P49146 1/20 0.51
▸ NPY5R Q15761 1/20 0.51
▸ QRFPR Q96P65 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30924745 0.93 NPY4R (0.57) IL23RTFPINPY4RNPY1RNPY2R
SCHEMBL30924731 0.93 NPY4R (0.57) IL23RTFPINPY4RNPY1RNPY2R
SCHEMBL30924741 0.90 TFPI (0.57) IL23RTFPINPY4RNPY1RNPY2R
SCHEMBL30880895 0.89 OPRM1 (0.60) IL23RTFPINPY4RNPY1RNPY2R
SCHEMBL30924739 0.89 QRFPR (0.53) IL23RTFPINPY4RNPY1RNPY2R
SCHEMBL30924755 0.86 IL23R (0.58) IL23RTFPINPY4RNPY1RNPY2R
SCHEMBL30512013 0.85 NPY4R (0.52) TFPINPY4RNPY1RNPY2RNPY5R
SCHEMBL29805234 0.84 QRFPR (0.58) TFPINPY4RNPY1RNPY2RNPY5R
SCHEMBL30725661 0.84 NPY4R (0.57) NPY4RNPY1RNPY2RNPY5R
SCHEMBL30450082 0.84 TFPI (0.60) TFPINPY4RNPY1RNPY2RNPY5R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250026787-A1 PEPTIDES AND METHODS FOR REDUCING SKIN PIGMENTATION GLO PHARMA, INC. 2025-01-23 — — US disclosed
US-12162956-B2 Peptides and methods for reducing skin pigmentation GLO PHARMA, INC. (US) 2024-12-10 — — US disclosed
US-20240190917-A1 PEPTIDES AND METHODS FOR REDUCING SKIN PIGMENTATION GLO PHARMA, INC. 2024-06-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240190917-A1 PEPTIDES AND METHODS FOR REDUCING SKIN PIGMENTATION MC1R, TYR, MC5R IL23R 2274/4885TFPI 918/4885NPY4R 66/4885
US-12162956-B2 Peptides and methods for reducing skin pigmentation MC1R, TYR, MC5R IL23R 2274/4885TFPI 918/4885NPY4R 66/4885
US-20250026787-A1 PEPTIDES AND METHODS FOR REDUCING SKIN PIGMENTATION MC1R, TYR, MC5R IL23R 2274/4885TFPI 918/4885NPY4R 66/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback